InVivo Therapeutics Announces Webcast for Annual Shareholders Meeting to Be Held on May 30th

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that the Company will be conducting a webcast of the Annual Shareholders Meeting scheduled for Wednesday, May 30, 2012 at 9:00 a.m. Eastern Daylight Time at One Broadway, 5th Floor, Cambridge, MA 02142.

The webcast can be accessed by interested shareholders and other parties at http://mp163419.cdn.mediaplatform.com/163419/wc/mp/4000/11124/14575/15458/Lobby/default.htm. The meeting will also be accessible by telephone in listen-only mode. From the U.S., please dial 1-877-941-2068; from outside the U.S. please dial 1-480-629-9712. All participants should reference conference I.D. 4543212. Slides from the meeting will be available to those viewing the webcast,and a replay of the webcast including presentation slides will also be available under the Investor Relations section of the InVivo Therapeutics website within 24 hours.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed from traumatic spinal cord injuries. The company was founded in 2005 based on proprietary technology co-invented by Robert S. Langer, ScD. Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011, the company earned the prestigious 2011 David F. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, MA. For more details, visit http://www.invivotherapeutics.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Companys ability to sell additional shares of common stock and warrants to purchase common stock at additional closings, the Companys ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Companys products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Companys business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including our Form 10-K and Form 10-Qs and our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.

View post:
InVivo Therapeutics Announces Webcast for Annual Shareholders Meeting to Be Held on May 30th